{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:09:30Z","timestamp":1777918170186,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[1983,12,1]],"date-time":"1983-12-01T00:00:00Z","timestamp":439084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[1983,12]]},"abstract":"<jats:p>\n                    Twenty-six patients affected by acute leukemia were treated with 4-demethoxydaunorubicin (idarubicin), a new anthracycline compound which in experimental leukemias showed an anti-tumoral activity superior to daunorubicin (DNR) and doxorubicin (DX), with a higher ratio of active to cardiotoxic doses. A group of 16 patients in relapse received idarubicin at a dosage of 5\u20136 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/day for 3 consecutive days; a second group of 6 relapsing and 4 previously untreated cases was treated with a sequential combination of idarubicin and arabinosyl cytosine. In all patients, a significant fall of bone marrow and peripheral blast cells was obtained. These preliminary results suggest that idarubicin has a therapeutic activity against human acute leukemias usually responsive to DNR or DX. The duration of myelosuppression varied from 7 to 50 days, leading in some cases to a high risk of infections. As regards other toxic effects (gastrointestinal, hepatic and acute cardiac toxicity, alopecia), idarubicin appears to be, in our experience, a well-tolerated drug; however, it is too early to comment on delayed cardiac effects.\n                  <\/jats:p>","DOI":"10.1177\/030089168306900605","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T05:43:28Z","timestamp":1523943808000},"page":"515-519","source":"Crossref","is-referenced-by-count":15,"title":["Therapeutic Activity of 4-Demethoxydauno-Rubicin (Idarubicin) in Adult Acute Leukemia"],"prefix":"10.1177","volume":"69","author":[{"given":"Giorgio","family":"Lambertenghi-Deliliers","sequence":"first","affiliation":[{"name":"Istituto di Clinica Medica I, Universit\u00e0 degli Studi di Milano, Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Pogliani","sequence":"additional","affiliation":[{"name":"Istituto di Clinica Medica I, Universit\u00e0 degli Studi di Milano, Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna T.","family":"Maiolo","sequence":"additional","affiliation":[{"name":"Istituto di Clinica Medica I, Universit\u00e0 degli Studi di Milano, Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Pacciarini","sequence":"additional","affiliation":[{"name":"Farmitalia Carlo Erba S.p.A., Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elio E.","family":"Polli","sequence":"additional","affiliation":[{"name":"Istituto di Clinica Medica I, Universit\u00e0 degli Studi di Milano, Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1983,12,1]]},"reference":[{"key":"bibr1-030089168306900605","first-page":"829","volume":"60","author":"Arcamone F.","year":"1976","journal-title":"Cancer Treat Rep."},{"key":"bibr2-030089168306900605","doi-asserted-by":"publisher","DOI":"10.1007\/BF00172075"},{"key":"bibr3-030089168306900605","first-page":"835","volume":"63","author":"Casazza A.M.","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"bibr4-030089168306900605","first-page":"16","volume":"63","author":"Casazza A.M.","year":"1979","journal-title":"(Abstract) Proc. Am. Assoc. Cancer Res."},{"key":"bibr5-030089168306900605","doi-asserted-by":"publisher","DOI":"10.1177\/030089168006600503"},{"key":"bibr6-030089168306900605","first-page":"893","volume":"61","author":"Di Marco A.","year":"1977","journal-title":"Cancer Treat. Rep."},{"key":"bibr7-030089168306900605","doi-asserted-by":"publisher","DOI":"10.1159\/000401466"},{"key":"bibr8-030089168306900605","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(82)90133-X"},{"key":"bibr9-030089168306900605","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb01158.x"},{"key":"bibr10-030089168306900605","first-page":"125","author":"Lambertenghi-Deliliers G.","journal-title":"4-Demethoxydaunorubicin (IMI 30) in acute leukemias: a preliminary report."},{"key":"bibr11-030089168306900605","first-page":"380","author":"Lambertenghi-Deliliers G.","journal-title":"4-Demethoxydaunorubicin (IMI 30) in the treatment of adult acute leukemia."},{"key":"bibr12-030089168306900605","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb01159.x"},{"key":"bibr13-030089168306900605","first-page":"45234528","volume":"37","author":"Supino R.","year":"1977","journal-title":"Cancer Res."},{"key":"bibr14-030089168306900605","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820415)49:8<1524::AID-CNCR2820490803>3.0.CO;2-U"},{"key":"bibr15-030089168306900605","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V60.2.454.454"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089168306900605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089168306900605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:32:42Z","timestamp":1777660362000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089168306900605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1983,12]]}},"alternative-id":["10.1177\/030089168306900605"],"URL":"https:\/\/doi.org\/10.1177\/030089168306900605","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,12]]}}}